Patent Information:
For Information, Contact:
Rachel Colman
Senior Business Manager
UCL Business PLC
(0)20 7636 5422

Neidle_Quadruplex-binding compounds - A novel anticancer strategy

Case ID:
Web Published:

Available For: Exclusive Licensing


{{start}} We have a first-in-class optimized small-molecule drug candidate ready for IND enabling studies with superior efficacy and activity against pancreatic cancer compared to existing agents, together with a distinct mechanism of action.{{end}}

<h2>The Technology and its Advantages</h2>

The development of a malignancy within the pancreas is a multistep process, several key oncogenes must be activated and tumor suppressor genes inactivated in order for cells to proliferate indiscriminately. We have developed a lead compound through rounds of chemistry optimisation which shows efficacy in several animal models tested. The molecule presents a novel mechanism of action where it targets G-quadruplex structures present on multiple gene promoters, allowing us to control the expression of several oncogenes, rendering the development of drug resistance unlikely.

<h2>Market Opportunity</h2>

Improvements in prevention, detection and treatment have happened over recent years, however there is still a large unmet need in a number of hard to treat cancers, examples including pancreatic cancer, prostate cancer, gastro-intestinal cancer and non-small-cell lung cancer.

<h2>Intellectual Property Status</h2>

Patent portfolio filed worldwide.

<h2>Further Information</h2>

Please contact, Rachel Colman |T: +44 (0)20 7679 9000 | E:


© 2021. All Rights Reserved. Powered by Inteum